Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jul 2

PMID 38952584

Authors

Precious O Idogun

Said Hafez-Khayyata

Daniel Ezekwudo

Affiliations

Soon will be listed here.

Abstract

Guillain-Barré syndrome (GBS) resulting from the use of immune checkpoint inhibitors (ICIs) is relatively uncommon but has been reported. Herein, we discuss a case of a 67-year-old patient who received neoadjuvant ICI for treatment of non-small cell lung cancer and then presented with lower extremity weakness and areflexia, progressing to respiratory muscle and upper extremity weakness. Given the increasing use of ICI in cancer management, awareness of neurological autoimmune side effects is essential. ICI-mediated GBS can be severe and fatal if not diagnosed promptly. We discuss a case of ICI-induced GBS and review literature on current management approaches.

References

Pierrard J, Petit B, Lejeune S, Seront E . Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab. BMJ Case Rep. 2019; 12(8). PMC: 6720815. DOI: 10.1136/bcr-2019-230848. View

Lewis A, Chaft J, Girotra M, Fischer G . Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. Br J Anaesth. 2020; 124(3):251-260. PMC: 7890563. DOI: 10.1016/j.bja.2019.11.034. View

Thapa B, Khalid S, Vakili R, Ui J, Misbah S . Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer. Am J Ther. 2018; 25(6):e761-e763. DOI: 10.1097/MJT.0000000000000771. View

Farooq M, Aqeel S, Lingamaneni P, Pichardo R, Jawed A, Khalid S . Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(4):e227722. PMC: 9020216. DOI: 10.1001/jamanetworkopen.2022.7722. View

Baird-Gunning J, Weerasinghe D, Silsby M, Gawarikar Y, Carlino M, Smith J . Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma. Neurohospitalist. 2018; 8(4):191-193. PMC: 6146353. DOI: 10.1177/1941874418778957. View

Kyriazoglou A, Liontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S . Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. Clin Genitourin Cancer. 2019; 17(2):e360-e364. DOI: 10.1016/j.clgc.2018.11.022. View

Kennedy L, Salama A . A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020; 70(2):86-104. DOI: 10.3322/caac.21596. View

Gu Y, Menzies A, Long G, Fernando S, Herkes G . Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017; 45:14-17. DOI: 10.1016/j.jocn.2017.07.014. View

Yuen C, Kamson D, Soliven B, Kramer C, Goldenberg F, Rezania K . Severe Relapse of Vaccine-Induced Guillain-Barré Syndrome After Treatment With Nivolumab. J Clin Neuromuscul Dis. 2019; 20(4):194-199. DOI: 10.1097/CND.0000000000000230. View

10.

Schneiderbauer R, Schneiderbauer M, Wick W, Enk A, Haenssle H, Hassel J . PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Derm Venereol. 2016; 97(3):395-396. DOI: 10.2340/00015555-2548. View

11.

Mazzaschi G, Bordi P, Fioretzaki R, Gnetti L, Milanese G, Tommasi C . Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma. Clin Lung Cancer. 2019; 21(2):e65-e73. DOI: 10.1016/j.cllc.2019.11.001. View

12.

Sechi E, Zekeridou A . Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. J Thorac Oncol. 2020; 16(3):381-394. DOI: 10.1016/j.jtho.2020.11.005. View

13.

Li Y, Zhang X, Zhao C . Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. Biomed Res Int. 2021; 2021:9800488. PMC: 8390151. DOI: 10.1155/2021/9800488. View

14.

Jacob A, C Unnikrishnan D, Mathew A, Thyagarajan B, Patel S . A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016; 142(8):1869-70. DOI: 10.1007/s00432-016-2191-7. View

15.

Hegen H, Ladstatter F, Bsteh G, Auer M, Berek K, Di Pauli F . Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. Eur J Neurol. 2020; 28(3):965-973. PMC: 7898894. DOI: 10.1111/ene.14600. View

16.

McNeill C, Fehmi J, Gladwin J, Price C . A rare case of Miller Fisher variant of Guillain-Barr Syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep. 2019; 12(8). PMC: 6700679. DOI: 10.1136/bcr-2019-229443. View

17.

Gorson K, Ropper A, Muriello M, Blair R . Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996; 47(3):813-7. DOI: 10.1212/wnl.47.3.813. View

18.

Larkin J, Chmielowski B, Lao C, Hodi F, Sharfman W, Weber J . Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017; 22(6):709-718. PMC: 5469590. DOI: 10.1634/theoncologist.2016-0487. View

19.

Ding M, Deng C, Liu X, Jiang S, Gao Y, Fan D . Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil. Front Immunol. 2023; 14:1132692. PMC: 10200921. DOI: 10.3389/fimmu.2023.1132692. View

20.

Janssen J, Leow T, Herbschleb K, Gijtenbeek J, Boers-Sonderen M, Gerritsen W . Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature. J Immunother. 2021; 44(7):276-282. DOI: 10.1097/CJI.0000000000000364. View